who reports todayUS earnings, drawn as flowsMy portfolio

← Who reports today · Health Care

MRNA · Q2 2026

Archived report (Q2 2026). Latest deep dive →

US GAAP, Q2 2026 · quarter ended 06/30/2026 · released Jul 31

The quarter in brief

Revenue grew 2.1% y⁠/⁠y to $145M, operating margin −562.1% vs −638.7%, net loss $782M (vs net loss $825M a year earlier).

All figures in $M.

Sankey diagram of MRNA earnings report for Q2 2026: revenue, costs and profitNet product sales$94 · −17.5%Other revenue$51 · +82.1%Total revenue$145 · +2.1%Interest income$67 · −17.3%Net loss$782 · −5.2%Cost of sales$93 · −21.8%Research and development$651 · −7.0%Selling, general andadministrative$216 · −6.1%Other (expense) income,net−$19 · vs +$8Provision for income taxes$15
Sankey diagram of MRNA earnings report for Q2 2026: revenue, costs and profit
Line itemAmount and change
Net product sales$94 · −17.5%
Other revenue$51 · +82.1%
Total revenue$145 · +2.1%
Interest income$67 · −17.3%
Net loss$782 · −5.2%
Cost of sales$93 · −21.8%
Research and development$651 · −7.0%
Selling, general and administrative$216 · −6.1%
Other (expense) income, net−$19 · vs +$8
Provision for income taxes$15

Verdict: revenue grew 2.1% y/y to $145M, operating margin −562.1% vs −638.7%, net loss $782M (vs net loss $825M a year earlier).

Revenue was $87 million in the U.S. and $58 million in international markets; the FDA had set August 5 as its target (PDUFA) date for a decision on mFLUSIVA, the seasonal influenza vaccine candidate.

Source and notation

Source: Moderna press release, 8-K EX-99.1 of 07/31/2026 (SEC EDGAR). The chart figures were matched against the income statement in the release; revenue and net income match SEC XBRL. Other figures in the text are taken from the release. Loss layout: the Net loss node ($782M) is the total amount by which costs, expenses and taxes exceeded revenue and interest income; it is not a source of funds. The bands show how the chart allocates that total shortfall, and the $67M of interest income, across expense and tax lines; this allocation is a display convention that depends on the order of the lines and is not reported in the statement. In the income statement, interest income of $67M is recorded below the operating loss of $815M and, with other expense of $19M, leads to a loss before income taxes of $767M.

Open as an image: MRNA, Q2 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0

Cite / embed this chart

Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).

Credit line
Chart: “MRNA Q2 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/mrna/q2-2026. Licensed under CC BY 4.0.
HTML: image with link and credit
<figure>
  <a href="https://whoreportstoday.com/t/mrna/q2-2026"><img src="https://whoreportstoday.com/t/mrna/q2-2026/sankey.png" alt="MRNA Q2 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a>
  <figcaption>Source: <a href="https://whoreportstoday.com/t/mrna/q2-2026">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption>
</figure>
Direct link to the image (PNG)
https://whoreportstoday.com/t/mrna/q2-2026/sankey.png
Link for your article text
<a href="https://whoreportstoday.com/t/mrna/q2-2026">MRNA Q2 2026 earnings chart (Who Reports Today)</a>

This is an archived report: the image at this link won’t change. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.

MRNA — Moderna is a biotechnology company that develops and sells mRNA medicines, including vaccines against COVID-19 (Spikevax, mNEXSPIKE) and RSV (mRESVIA), with a pipeline in influenza, oncology and rare diseases.

Headquarters: Cambridge, Massachusetts.

Heads-up

More reports: MTD · Q3 2026 · PFE · Q3 2026 · PODD · Q3 2026 · REGN · Q3 2026 · RMD · Q1 FY2027 · RVTY · Q3 2026 · SOLV · Q3 2026 · STE · Q2 FY2027 · SYK · Q3 2026 · TECH · Q1 FY2027 · all reports

Company reports

Q3 2026latest breakdownRevenue grew 29.2% y/y to $1.31B, operating margin 9.9% vs −25.6%, net income $162M.
Q2 2026Revenue grew 2.1% y/y to $145M, operating margin −562.1% vs −638.7%, net loss $782M (vs net loss $825M a year earlier).

Cookies the site needs and, with your consent, Google Analytics — privacy policy